Introduction: Tumor sidedness and RAS/BRAF status have changed the treatment landscape of metastatic colorectal cancer (mCRC). This study was performed to understand the first line choices of Brazilian oncologists for patients with advanced/unresectable metastatic colorectal cancer (mCRC), especially in the emergent context of tumor sidedness and RAS/BRAF V600E status. Methods: This is a cross-sectional electronic survey composed of 6 questions, which was sent to Brazilian medical oncologists and medical oncology groups by email, Facebook and/or WhatsApp. The survey instrument assessed current practices in terms of first-line treatment choices for fit patients with mCRC, including left-sided wildtype (wt)-RAS/wt-BRAFV600E, right-sided wt-RAS/wt-BRAFV600E and any-side mutated RAS, considering that all drugs were available. The instrument also elicited data about years in practice in Medical Oncology, gender and how much of each oncologist's practice was dedicated to gastrointestinal tumors (GI). Those with at least 75% of their time dedicated to patients with GI malignancies were considered specialists.
The questionnaire was open for answers for 12 days. Results: The survey was completed during a 12-day period by 222 medical oncologists from across the country. Because the survey was not sent to all individual emails, we could not estimate the response rate but for those who responded, the completion rate was 100%. Most oncologists were male (57.2%) and were in Oncology practice for less than 10 years (61.7%). Only 9.4% of the participants were specialists in GI tumors. For left-sided, wt-RAS/wt-BRAFV600E mCRC, most oncologists (81.9%) chose first line chemotherapy (CT) þ anti-EGFR therapy, with 53.2% of them preferring FOLFIRI as the CT backbone. Meanwhile, for right-sided, wt-RAS/wt-BRAFV600E mCRC, the majority (71.1%) would offer CT þ bevacizumab (53.7% with FOLFOX, 31.6% with FOLFIRI and 14.5% with FOLFOXIRI). For mutated-RAS mCRC, most oncologists (51.8%) decided for FOLFOX þ bevacizumab (33.6% for FOLFIRI þ bevacizumab and 14.5% for FOLFOXIRI þ bevacizumab). Conclusion: This is the first study conducted among Brazilian oncologists to investigate treatment preferences according to sidedness and RAS/BRAF V600E status. Our survey indicates that tumor sidedness influences the choice of both CT backbone and monoclonal antibody in unresectable wt-RAS mCRC.
P À 266 Retrospective analysis of clinical factors associated with a greater response. Methods: We collected retrospectively the clinical data of 98 patients who had received treatment with Trifluridine and Tipiracil until January 2018 in seven different hospitals in Madrid. Results: The mean age at first use of Trifluridine and Tipiracil was 666 9.45 years, 57.5% were men and 42.3% were women, most of them in good performance status (ECOG 0-1: 71.2%), 27.8% had ECOG !2 when started Trifluridine and Tipiracil. All of the patients were diagnosed of metastatic colorectal cancer (73.2% had liver metastases, 58.2% lung metastases and 30.9% peritoneal metastases). Tumor localization was: 73.2% left colon, 24.8% right colon, and only 2% small intestine or 1% two synchronous colonic tumors. KRAS mutations were found in 62.9%, NRAS mutations in 17.4% and BRAF mutations were found in 5.4% patients. The median of prior lines of chemotherapy was three. The median progression free survival was 3 months (95% CI 2.65 -3.36). The median overall survival was 5 months (95% CI 4.23-5.78). The median duration of treatment was 3 cycles. 23.7% patients had an adverse event that led to treatment withdrawal. The requirement of dose-reduction was associated with longer PFS (4 months vs 3 months, p ¼ 0.002) and OS (14 months vs 5 months, p ¼ 0.017). The existence of BRAF mutation was also associated with shorter PFS (1 month vs 3 months, p ¼ 0.002) and OS (1 month vs 5 months, p ¼ 0.000). There was no statistically significant difference of PFS and OS according to primary tumor location. Conclusion: Trifluridine and Tipiracil is effective in metastatic colorectal cancer (in patients with !2 lines of treatment). The OS (5 months) and PFS (3 months) reached in our study in real clinical practice are consistent with findings from previous studies. Mutational status of BRAF was statistically significant associated with shortened PFS and OS. Dose reduction during treatment is associated with Trifluridine and Tipiracil efficacy in terms of prolonged OS and PFS. Differences between groups were determined according to chi-square test; OS and PFS were estimated by Kaplan-Meier method and multivariate analysis according to Cox regression; a significant level of 0.05 was chosen to assess the statistical significance. Results: We included 65 patients. Fifteen patients had RC tumors (cecum: 5; ascendant: 1; hepatic flexure: 1; proximal transverse: 6) and 50 had LC tumors (splenic flexure: 3; descending: 3; sigmoid: 33; rectum: 11). The median age at diagnosis of metastatic disease was 63 years-old . Thirty eight patients (58.5%) were treated with cetuxiwith panitumumab. Concomitant chemotherapy protocol was (63.1%), FOLFOX in 19 (29.2%) and irinotecan in 5 (7.7%). significant differences between RC and LC groups. The 8 months 
